Table 2.

Drugs targeting monocyte/macrophage populations in preclinical and clinical studies

Drugs	Target and mechanism	Cancer types	National Clinical Trial number	Status	Ref.
FPA008, PLX3397, IMC-CS4, AMG 820, PLX7486,	CSF1R blocking antibodies or inhibitors	Advanced tumors, pancreatic cancer	NCT01346358 NCT02452424 NCT03336216 NCT01349036	Phase I/II	83,173
MLN1202, PF-04136309	CCR2 blocking antibodies or antagonists	Bone metastasis, pancreatic cancer	NCT01015560 NCT01413022 NCT02732938	Phase II	83,189
CP-870,893, APX005M	CD40 agonist antibodies	Melanoma, breast cancer, non-small cell lung cancer, renal cell cancer, esophageal cancer, brain tumor	NCT02157831 NCT01456585 NCT03165994 NCT03123783 NCT03719430 NCT04130854 NCT02482168	Phase I/II	90,190
IPI-549	PI3Kγ inhibitor	Advanced solid tumors	NCT02637531 NCT03961698	Phase I/II	91
Hu5F9-G4, CC-95251, SRF231	SIRPα or CD47 blocking antibodies, target CD47/SIRPα axis	Lymphoma, leukemia, colorectal cancer	NCT03783403 NCT02953782 NCT03558139 NCT02216409	Phase I/II	191
AZD9150	Stat3 inhibitors	Advanced pancreatic, non-small cell lung cancer, colorectal cancer	NCT03421353 NCT03394144 NCT01839604 NCT03334617 NCT02499328	Phase II	192
Reparixin, AZD5069, SX-682	CXCR1/2 antagonist	Metastatic breast cancer, Colon cancer, Prostate cancer	NCT02001974 NCT02370238 NCT02499328 NCT04599140	Phase I/II	193